Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/Phase 2 Open-label Single Arm Study With Dose Escalation (Part A), and Dose Expansion (Part B) Parts to Evaluate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants 10 to 55 Years Old With Non-congenital Myotonic Dystrophy Type 1

NCT06844214 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06844214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06844214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/Phase 2 Open-label Single Arm Study With Dose Escalation (Part A), and Dose Expansion (Part B) Parts to Evaluate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants 10 to 55 Years Old With Non-congenital Myotonic Dystrophy Type 1
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 23, 2025
Completion date
April 27, 2032
Enrollment
32 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

myotonic dystrophy